Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear

 
• By Joseph Haas
  
People_Queue
Neurocrine's Ongentys will take on entrenched generics, but has differentiating factors
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip